KA
ALDX icon

Kozak & Associates’s Aldeyra Therapeutics ALDX Stock Holding History

Kozak & Associates’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,000
Closed -$4.52K – 453
2025
Q2 		$4.52K Buy
+1,000
New +$2.58K ﹤0.01% 300

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Kozak & Associates's ALDX Position: Q3 2025 in Review

Kozak & Associates sold out of Aldeyra Therapeutics (ALDX) in Q3 2025, closing a stake of 1,000 shares — an estimated $4.52K sold.

Kozak & Associates first reported a position in ALDX in Q2 2025 and held it in 1 quarter. The position peaked at $4.52K in Q2 2025. 130 funds tracked by Wall St. Rank hold ALDX as of Q3 2025.

  • Kozak & Associates reported no remaining Aldeyra Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Kozak & Associates sold 1,000 Aldeyra Therapeutics shares in Q3 2025, an estimated $4.52K.
  • Kozak & Associates first reported a position in Aldeyra Therapeutics in Q2 2025 and held it in 1 quarter.
  • Kozak & Associates's Aldeyra Therapeutics position peaked at $4.52K in Q2 2025.
  • 130 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2025.

Based on Kozak & Associates's 13F filing for Q3 2025, filed 18 Nov 2025.